Principal Financial Group Inc. Has $5.35 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Principal Financial Group Inc. boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 102.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 290,414 shares of the company’s stock after purchasing an additional 146,621 shares during the period. Principal Financial Group Inc. owned 0.14% of Hims & Hers Health worth $5,349,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the last quarter. Quest Partners LLC lifted its position in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares in the last quarter. CWM LLC grew its stake in shares of Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. Van ECK Associates Corp acquired a new stake in shares of Hims & Hers Health in the second quarter valued at approximately $111,000. Finally, Amalgamated Bank raised its position in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after purchasing an additional 2,354 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, COO Melissa Baird sold 58,750 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $21.04, for a total value of $1,236,100.00. Following the completion of the sale, the chief operating officer now owns 630,166 shares of the company’s stock, valued at approximately $13,258,692.64. This represents a 8.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. The trade was a 84.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,056,183 shares of company stock worth $21,501,682. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Down 7.4 %

Hims & Hers Health stock opened at $21.80 on Thursday. Hims & Hers Health, Inc. has a twelve month low of $7.51 and a twelve month high of $30.44. The company has a 50 day moving average of $20.21 and a 200-day moving average of $19.09. The stock has a market capitalization of $4.76 billion, a PE ratio of 49.55 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.04) EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on HIMS shares. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.